Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Analysts

Qiagen N.V. (NYSE:QGEN) has been given a consensus rating of “Hold” by the ten research firms that are covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $49.6111.

A number of analysts recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday. Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research note on Sunday. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $55.00 to $50.00 in a research note on Thursday, December 11th. Finally, Barclays reaffirmed an “overweight” rating and issued a $55.00 price objective (up previously from $53.00) on shares of Qiagen in a research report on Monday, December 15th.

Institutional Investors Weigh In On Qiagen

Several large investors have recently added to or reduced their stakes in the stock. SVB Wealth LLC purchased a new position in shares of Qiagen during the first quarter worth approximately $31,000. Danske Bank A S bought a new position in Qiagen in the third quarter worth approximately $36,000. Smartleaf Asset Management LLC increased its holdings in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during the period. MAI Capital Management increased its holdings in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares during the period. Finally, Farther Finance Advisors LLC raised its position in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Down 0.3%

Shares of NYSE QGEN opened at $45.48 on Thursday. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. Qiagen has a 12-month low of $37.63 and a 12-month high of $51.88. The firm’s 50-day moving average price is $46.21 and its 200-day moving average price is $47.12. The stock has a market capitalization of $10.11 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 2.33 and a beta of 0.68.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.03. The company had revenue of $532.58 million for the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.57 earnings per share. On average, equities research analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.